Qiagen N.V. is a global provider of molecular diagnostics and sample-to-insight technologies used to isolate and analyze DNA and RNA. This third-quarter 2026 earnings report carries unusual weight because it lands against a major corporate backdrop: on October 22, 2026, QGEN announced a definitive agreement to be acquired by EQT Private Equity in an all-cash deal valued at roughly €10.8 billion. As a result, investors are weighing solid operational momentum against the mechanics of the pending transaction. The company suspended its annual outlook and skipped its usual conference call, making these reported figures one of the clearest remaining snapshots of underlying business performance.
QGEN reported third-quarter 2026 net sales of $548 million, an increase of 3% over the prior-year period and in line with its preliminary announcement. Adjusted diluted EPS was $0.65, up 7% from $0.61 a year earlier and above the company's outlook of at least $0.62 at constant exchange rates (CER, which strips out currency fluctuations). Reported diluted EPS, which includes acquisition-related items, fell to $0.51 from $0.60.
Adjusted operating income rose 6% to $167 million, driving the adjusted operating income margin to 30.4%, up from 29.6% in the third quarter of 2025. Management attributed the improvement to sales growth, a growing contribution from higher-margin consumables, and efficiency gains that helped fund investments in Parse Biosciences, acquired in late 2025. Operating cash flow reached $447 million for the first nine months of 2026. The adjusted EPS figure exceeded consensus estimates of roughly $0.62 to $0.63, while revenue came in above the approximately $538 million analysts had expected. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
QGEN stock has been trading largely in step with the terms of the EQT transaction rather than its quarterly fundamentals. The agreement values the company at €46.50 per share, representing a premium of about 40% to Qiagen's closing price on July 8, 2026. With shares hovering near $50 in U.S. trading, the stock sits just below the implied offer, leaving limited room tied to operating results. Sentiment has shifted decisively toward deal mechanics: several analysts downgraded the stock to a neutral or hold stance following the announcement, and the suspension of guidance has removed a key valuation anchor. As a result, the market's response to these earnings is expected to be muted relative to a typical reporting period.
Looking ahead, the dominant factor for Qiagen shareholders is the progress of the EQT acquisition. The offer process has not yet formally begun, and the tender offer document must first receive approval from Germany's BaFin regulator before it can be published. Investors will be watching the timing of that publication, the terms of any offer, and the completion of regulatory approvals across relevant jurisdictions.
On the operational side, the third-quarter results showed a constructive mix, with consumables accounting for the large majority of sales and growth drivers contributing about $415 million in revenue, up 7% year over year. That strength was partially offset by declines in the rest of the portfolio, which is worth monitoring for signs of stabilization.
Because Qiagen has suspended its full-year 2026 guidance, investors no longer have the company's forward targets as a reference point. Without a conference call, visibility into management's near-term expectations is reduced. The key question for shareholders is no longer solely about margins or revenue growth, but whether the transaction closes on the announced terms and timeline.
I often turn to Tickeron’s AI Screener when evaluating names like QGEN alongside peers in diagnostics. It lets me apply custom filters for technical patterns, fundamentals, and performance metrics, helping surface comparable setups quickly. In this case, it confirmed the relative stability in the sector and highlighted a few other life-sciences names worth tracking during the deal period. The tool has become a regular part of my workflow for staying objective when news flow dominates price action.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
QGEN's Aroon Indicator triggered a bullish signal on November 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 194 similar instances where the Aroon Indicator showed a similar pattern. In 104 of the 194 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 54%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +0.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where QGEN advanced for three days, in 140 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 53%.
The 10-day RSI Indicator for QGEN moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 12 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 38%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QGEN as a result. In 50 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 54%.
The Moving Average Convergence Divergence Histogram (MACD) for QGEN turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 21 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 51%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 50%.
QGEN broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.095) is normal, around the industry mean (67.298). P/E Ratio (25.318) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (1.201) is also within normal values, averaging (3.473). QGEN's Dividend Yield (0.028) is considerably higher than the industry average of (0.002). P/S Ratio (4.255) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. QGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of sample and assay technology products for preanalytical sample preparations
Industry MedicalSpecialties